Dr. Daniel Geiger
Dr. Daniel Geiger is a lawyer, a medical law specialist and a business mediator. He is a partner in the law firm Geiger Nitz + Partner Rechtsanwälte.
After studying law in Freiburg and Salzburg, he was awarded a doctorate for his dissertation on a health law topic at the Institute for German, European and International Medical Law, Health Law and Bioethics at the universities of Heidelberg and Mannheim under Prof. Dr. Taupitz. He began his professional career in 2006 as a lawyer in the medical law team of an international law firm in their Hamburg office. In 2007 he joined the legal department of a research-based pharmaceutical company. There he attained the positions of Senior Legal Counsel, Head of Governance Risk & Compliance and Compliance Officer. In 2012, he transferred to a leading medical law firm in Berlin, initially as an associated partner, and became a full partner there in 2015. On 1.1.2017, he founded the law firm Geiger + Partner which has traded as Geiger Nitz und Partner since 1.1.2018.
Since 2008, he has been a member of various work committees in pharmaceutical industry associations (until 2012: VfA, since 2012: BPI). From 2009 until 2011, he was also a member of the board of the Voluntary Self-Regulation of the Pharmaceutical Industry Association (FSA). Since 2012, he has been a member of the “Healthcare Compliance Advisory Board” of the Pharmaceuticals and Cooperation in Healthcare Association (AKG), since 2014, a member of the Anti-Corruption Work Group of the Federal Pharmaceutical Industry Association (BPI) and since 2015, chairman of the “Healthcare Work Group” of the German Institute for Compliance (DICO).
He mainly advises healthcare service providers and companies regarding criminal law prevention and healthcare compliance issues. In this context, he provides comprehensive advice regarding collaborations in the healthcare sector. He also focuses on representing companies and individuals in civil disputes, in particular competition-related disputes, associations proceedings and criminal law investigations. He provides comprehensive advice regarding pharmaceutical law issues, especially those concerning clinical research as well. At the same time, he uses his legal knowledge and experience as the co-founder of a start-up in the area of digital health in order to offer advice on (start-up) projects in this field.
He teaches medical criminal law in the Medical Law LL.M. program at the Dresden International University (DIU), lectures in the area of healthcare compliance in the “Pharmaceutical Law” LL.M. program at Philipps Universität in Marburg and at the School of Governance Risk & Compliance at the Steinbeis-Hochschule Berlin. He has written numerous specialist articles on pharmaceutical law, healthcare compliance and medical criminal law.
His competitors describe him as “extremely skilled in the area of compliance” (JUVE Handbuch 2014/2015), while his clients report that he has “profound expertise” in medical products advertising law (JUVE Handbuch 2016/2017). In 2017, the American survey “Best Lawyers in Germany” nominated him to the Pharmaceuticals Law category. This was followed by a Handelsblatt nomination in the same category to the “Germany’s best lawyers in 2017” list.
He advises clients in German and English.